Technical Analysis for ARGX - argenx SE
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -0.01% | |
| Gapped Up | Strength | -0.01% | |
| Calm After Storm | Range Contraction | 5.87% | |
| Stochastic Reached Oversold | Weakness | 5.87% | |
| Down 3 Days in a Row | Weakness | 5.87% | |
| Down 4 Days in a Row | Weakness | 5.87% | |
| Down 5 Days in a Row | Weakness | 5.87% | |
| Oversold Stochastic | Weakness | 5.87% | |
| 20 DMA Resistance | Bearish | 4.85% | |
| MACD Bearish Centerline Cross | Bearish | 4.85% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 1 hour ago |
| Fell Below 20 DMA | about 1 hour ago |
| 20 DMA Support | about 1 hour ago |
| 10 DMA Resistance | about 21 hours ago |
| 20 DMA Resistance | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
argenx SE Description
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Lymphoma Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Myasthenia Gravis Dyslipidemia Hematological Cancers Myasthenia Thrombocytopenia Skin Inflammation Janus Kinase Inhibitor Rgx Therapies For The Treatment Of Autoimmune Diseases Treatment Of Hematological Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 550.76 |
| 52 Week Low | 327.73 |
| Average Volume | 246,273 |
| 200-Day Moving Average | 436.01 |
| 50-Day Moving Average | 381.03 |
| 20-Day Moving Average | 376.15 |
| 10-Day Moving Average | 380.99 |
| Average True Range | 12.96 |
| RSI (14) | 49.24 |
| ADX | 17.42 |
| +DI | 24.68 |
| -DI | 28.39 |
| Chandelier Exit (Long, 3 ATRs) | 361.71 |
| Chandelier Exit (Short, 3 ATRs) | 391.65 |
| Upper Bollinger Bands | 399.98 |
| Lower Bollinger Band | 352.31 |
| Percent B (%b) | 0.52 |
| BandWidth | 12.67 |
| MACD Line | -2.42 |
| MACD Signal Line | -0.96 |
| MACD Histogram | -1.4585 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 408.97 | ||||
| Resistance 3 (R3) | 406.68 | 393.71 | 403.64 | ||
| Resistance 2 (R2) | 393.71 | 385.56 | 394.86 | 401.86 | |
| Resistance 1 (R1) | 385.34 | 380.53 | 389.53 | 387.63 | 400.08 |
| Pivot Point | 372.37 | 372.37 | 374.47 | 373.52 | 372.37 |
| Support 1 (S1) | 364.00 | 364.22 | 368.19 | 366.29 | 353.84 |
| Support 2 (S2) | 351.03 | 359.19 | 352.18 | 352.06 | |
| Support 3 (S3) | 342.66 | 351.03 | 350.29 | ||
| Support 4 (S4) | 344.95 |
